Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS
- None.
- None.
The introduction of Silk Road Medical's ENROUTE Transcarotid Neuroprotection System PLUS represents an advancement in medical device technology, specifically within the vascular surgery sector. The enhanced features of smoother arterial sheath insertion and greater flow precision are not just incremental improvements but are indicative of the company's investment in R&D and responsiveness to physician feedback. These improvements could potentially lead to increased adoption rates of the TCAR procedure, which is already noted for its low periprocedural stroke rates and favorable recovery experience compared to traditional open surgery.
From an investment perspective, the launch of NPS PLUS could signify an uptick in Silk Road Medical's revenue stream if the product successfully displaces older models and is adopted as a standard tool for TCAR procedures. Given that the device aims to streamline the surgical workflow, it could also reduce operation times and costs for healthcare providers, which is a compelling value proposition in today's cost-conscious healthcare environment.
Carotid artery disease treatment is a niche but significant segment of the cardiovascular market. The deployment of NPS PLUS could capture additional market share for Silk Road Medical, especially if the device demonstrates a tangible benefit in terms of procedural efficiency and outcomes. Market penetration will likely depend on the company's ability to communicate these benefits to physicians and hospitals effectively.
It's also essential to consider the competitive landscape. If competitors lack a comparable innovation, Silk Road Medical might gain a competitive edge. However, if competitors are close to releasing similar upgrades, the window for market impact could be narrow. The company's long-term success will hinge on its ability to maintain a pipeline of innovative products and secure insurance coverage and reimbursement, which can be a significant barrier to adoption for new medical technologies.
The launch of a new product like the ENROUTE NPS PLUS could be a driver for stock performance, particularly if it leads to market share gains and improved financial metrics such as margins and earnings per share. The initial market reaction will depend on the perceived value of the improvements in the NPS PLUS and the company's ability to execute a successful roll-out.
Investors will be watching closely for early adoption indicators, such as partnerships with hospitals and testimonials from key opinion leaders in the vascular surgery field. Additionally, they will be interested in the impact of this product launch on the company's operating expenses, given that new product launches can be capital-intensive. Long-term, the ability of Silk Road Medical to leverage this product to drive growth will be critical in assessing the company's financial health and stock valuation.
SUNNYVALE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE® Transcarotid Neuroprotection System PLUS (“NPS PLUS”), a key component of the TCAR® portfolio. This next generation device builds upon the prior ENROUTE Transcarotid Neuroprotection System to deliver smoother arterial sheath insertion, greater flow precision, and a simplified prep experience for surgical teams, all while maintaining unparalleled neuroprotection during the TCAR procedure.
“With the launch of the NPS PLUS, we're thrilled to empower our TCAR-trained physicians with a solution that addresses their insights and feedback to further strengthen and streamline the TCAR procedure,” shared Chas McKhann, Chief Executive Officer of Silk Road Medical. “Our focus on new product innovation reflects our ongoing commitment to leadership in the treatment of carotid disease.”
TCAR combines direct carotid artery access with robust blood flow reversal, providing neuroprotection akin to open surgical techniques in a less invasive, more patient-friendly approach to treating carotid artery disease. During TCAR, the surgical team inserts a tube-like sheath into the carotid artery and connects it to the ENROUTE Neuroprotection System, which temporarily reverses blood flow. The system filters potentially dangerous debris from the blood to reduce intraprocedural stroke risk while the team uses a TCAR-specific balloon and stent to open the artery and contain the carotid artery disease. TCAR delivers less than
“Silk Road Medical's responsiveness to our feedback has provided us with better procedure predictability and a more streamlined workflow for our entire surgical team," remarked Brian Peterson, MD, FACS, FSVS of St. Luke’s Heart and Vascular Institute. "With over 500 TCAR procedures performed by our team, we view TCAR as a first-line treatment option for carotid disease and we’re excited about what these improvements mean for patient care.”
Click here for more information on the ENROUTE Neuroprotection System PLUS.
About TCAR with the ENROUTE Transcarotid Neuroprotection and Stent System
TCAR (Transcarotid Artery Revascularization) is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The ENROUTE Transcarotid Stent is intended to be used in patients at high risk and standard risk for complications from CEA, in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS) during the TCAR procedure. The ENROUTE Transcarotid NPS is a first in class device used to directly access the common carotid artery and initiate high-rate temporary blood flow reversal to protect the brain from stroke while delivering and implanting the ENROUTE Transcarotid Stent.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company with locations in Sunnyvale, California, and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called Transcarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.
| Investors: Marissa Bych Gilmartin Group investors@silkroadmed.com | Media: Michael Fanucchi Silk Road Medical mfanucchi@silkroadmed.com |
